Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Summary

This is a multi-center, randomized, open-label, parallel group study designed to evaluate efficacy and safety of fulvestrant followed, at progression, by examestane and everolimus versus examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR+ and HER2- LABC or MBC whose disease has progressed to NSAI in the adjuvant or metastatic setting.

Timeline

Start

2015-12

Primary completion

2018-01

Completion

2019-01

Drugs

Indications